Bristol-Myers Squibb HIV Drug Fast-Tracked

The US Food and Drug Administration has designated the Bristol-Mayers Squibb experimental HIV drug BMS-663068 as a breakthrough treatment, which could accelerate its approval.

The US drugmaker is currently running late-stage clinical tests with the drug, intended to be used with other antiretroviral drugs in adults who have already developed resistance to several other types of HIV treatments.

According to the National Institutes of Health, there are six classes of HIV drugs, and patients are typically treated with drugs from at least two different classes at any given time, but if they develop resistance to several types of drugs, their doctors may not be able to assemble an effective treatment regimen.

The company is studying BMS-663068 in patients who have two or fewer drug classes left to them. The new development, which the company said does not fit into the six current classes of HIV therapy, is designed to stick to HIV cells and stop them from binding to a type of white blood cell.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.